文献速递甲状腺疾病

甲状腺激素服药依从性与痴呆风险的关联

Association of Thyroid Hormone Medication Adherence With Risk of Dementia.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

这项基于人群的队列研究随访了41554例2004至2008年间新诊断甲状腺功能减退、年龄50岁及以上的老年人,截至2020年12月31日共识别2120例新发痴呆。按药物持有率(MPR)四分位分层,最高依从组(第四分位)较最低依从组(第一分位)总体痴呆风险降低14%(校正HR 0.86;95%CI 0.76-0.97);二分类分层中MPR≥0.8者阿尔茨海默病风险低于MPR<0.8者(校正HR 0.91;95%CI 0.84-0.99)。作者认为更好的甲状腺激素服药依从性可能有助于预防新诊断甲减老年人的新发痴呆,尤其是阿尔茨海默病。

要点

  • MPR最高四分位组较最低四分位组总体痴呆风险降低14%(校正HR 0.86;95%CI 0.76-0.97)。
  • MPR≥0.8者阿尔茨海默病风险低于MPR<0.8者(校正HR 0.91;95%CI 0.84-0.99)。
  • 甲状腺激素服药依从性与血管性痴呆之间未观察到一致性关联。

核心结论

  • 更好的甲状腺激素服药依从性可能有助于预防新诊断甲减老年人的新发痴呆,尤其是阿尔茨海默病。
  • 作者认为,除甲减症状缓解与心血管危险因素减少外,痴呆风险降低可能是甲状腺激素药物的另一潜在获益。

研究设计与样本

  • 基于人群的队列研究,随访新诊断甲减患者至发生痴呆、死亡或2020年12月31日(以最早者为准)。
  • 纳入2004至2008年间新诊断甲减并接受健康筛查的41554例50岁及以上老年人。
  • 采用多变量校正Cox比例风险回归评估痴呆风险。

主要发现

  • 共纳入5188例男性(12.5%)和36366例女性(87.5%),识别2120例新发痴呆。
  • 按MPR四分位分层,第四分位(最高依从)较第一分位(最低依从)总体痴呆风险降低14%(校正HR 0.86;95%CI 0.76-0.97)。
  • 甲状腺激素服药依从性与血管性痴呆之间未观察到一致性关联。
  • 按MPR二分类分层,MPR≥0.8者阿尔茨海默病风险低于MPR<0.8者(校正HR 0.91;95%CI 0.84-0.99)。

关键数值与推荐

  • MPR四分位分层:第四分位(最高依从)vs 第一分位(最低依从),总体痴呆校正HR 0.86;95%CI 0.76-0.97。
  • MPR二分类:≥0.8 vs <0.8,阿尔茨海默病校正HR 0.91;95%CI 0.84-0.99。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Recent studies suggest that hypothyroidism is a risk factor for dementia. Based on existing literature, it is unclear if treatment or compliance to treatment is associated with decreased dementia risk in hypothyroidism patients. OBJECTIVE: To determine the association between thyroid hormone medication adherence and risk of dementia. METHODS: A population-based cohort study following patients with newly diagnosed hypothyroidism until incidence of dementia, death, or December 31, 2020, whichever came earliest. The study comprised 41 554 older adults age 50 and above with newly diagnosed hypothyroidism between 2004 and 2008 who underwent health screening. Risk of dementia was evaluated using multivariable-adjusted Cox proportional hazards regression. RESULTS: Among 5188 men (12.5%) and 36 366 (87.5%) women, 2120 cases of incident dementia were identified. After stratification of the participants according to the interquartile range of the medication possession ratio (MPR), the fourth quartile (highest adherence) showed a 14% lower risk of overall dementia compared with the first quartile (lowest adherence) (adjusted hazard ratio 0.86; 95% CI 0.76-0.97). No consistent association was observed between thyroid hormone medication adherence and vascular dementia. After a dichotomous stratification of the MPR, higher MPR (≥0.8) showed a lower risk of Alzheimer disease (adjusted hazard ratio 0.91; 95% CI 0.84-0.99) than lower MPR (<0.8). CONCLUSION: Better adherence to thyroid hormone medication may be beneficial in preventing incident dementia, especially Alzheimer disease, in older adults with newly diagnosed hypothyroidism. Along with the resolution of hypothyroid symptoms and the reduction of cardiovascular risk factors, the reduction of dementia risk may be another potential benefit of thyroid hormone medication.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Han S, Jeong S, Choi S, et al. Association of Thyroid Hormone Medication Adherence With Risk of Dementia. J Clin Endocrinol Metab. 2023. PMID: 37515589. doi:10.1210/clinem/dgad447

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。